NIDA-1 P50 DA 018185: DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF R

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a human laboratory clinical pharmacology study to assess potential interactions between intravenous methamphetamine and rivastigmine, in order to assess the safety and the likely efficacy of rivastigmine for the treatment of methamphetamine dependence. Primary: ¿ To determine how treatment with an active medication, compared to placebo, alters cardiovascular effects produced by Methamphetamine ¿ To determine how treatment with an active medication, compared to placebo, alters subjective and reinforcing effects produced by methamphetamine. ¿ To determine how treatment with an active medication, compared to placebo, alters craving and drug-seeking behavior produced by methamphetamine. Secondary: To determine how treatment with an active medication, compared to placebo, alters neurocognitive functioning.